Lightstone Ventures
Portola Valley, California, United StatesFounded 2012
Lightstone Ventures is a global life-science venture capital firm founded in 2012, investing in biotech and medtech companies pioneering breakthroughs in therapeutics and medical devices. The firm builds companies from start-up through commercialization, with offices in Portola Valley, Boston, and Dublin.
34% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $68.7M (across 54 rounds with reported amounts).
Portfolio
49
Fund Size
$375M
Top Stage
Series A
Last 12 Mo
4
Team
MC
Mike Carusi
Managing Partner
CG
Caroline G.
Partner
CI
Christina Isacson
Partner
CK
Christina K. Isacson
Partner
HG
Hanson Gifford
Partner
KN
Kenneth Noonan
Venture Partner
JW
Jingjing Wang
Vice President
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
62 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| CCrystalys Therapeutics | Series B | $130M | Jul 2026 |
| CCrystalys Therapeutics Inc | Series B | $130M | Jul 2026 |
 PsiThera | Series A | $47.5M | Dec 2025 |
| CCrystalys Therapeutics Inc | Series A | $205M | Sep 2025 |
 ProVerum | Series B | — | Aug 2025 |
 Allay Therapeutics | Series D | $57.5M | Jun 2025 |
 Atsena Therapeutics | Series C | $150M | Apr 2025 |
 Reprieve Cardiovascular | Series B | $61M | Jan 2025 |
 Apreo Health | Series B | $130M | Jan 2025 |
| AApreo | Unknown | $130M | Jan 2025 |
 Fire1 | Unknown | $120M | Jan 2025 |
| Atsena Therapeutics | Series C | $150M | Jan 2025 |
| PPROVERUM LIMITED | Series B | $80M | Jan 2025 |
 Cala Health | Growth | $50M | Dec 2024 |
 Amber Therapeutics | Series A | $100M | Jun 2024 |
 Cerevance | Series C | $51M | Apr 2024 |
| Reprieve Cardiovascular | Series A | $42M | Jan 2024 |
 65LAB | Unknown | — | Oct 2023 |
 Tagworks Pharmaceuticals | Series A | $65M | Jun 2023 |
| TTagworks | Series A | $64M | Jun 2023 |
 Relievant Medsystems | Series G | $50M | Apr 2023 |
| RRelievant Medsystems, Inc. | Series G | $50M | Apr 2023 |
| Fire1 | Unknown | $25M | Mar 2023 |
 Volta Medical | Series B | — | Jan 2023 |
 Vigil Neuroscience | Series B | $90M | Jan 2023 |
Page 1 of 3
Top Co-Investors
New Enterprise Associates11 shared
Gilde Healthcare8 shared
OrbiMed7 shared
Atlas Venture7 shared
Cormorant Asset Management6 shared
Canaan Partners5 shared
Morgenthaler Ventures5 shared
Endeavour Vision5 shared
Osage University Partners5 shared
F-Prime Capital4 shared
Intuitive Ventures4 shared
GV4 shared
ARCH Venture Partners4 shared
Vensana Capital4 shared
RA Capital Management4 shared
Enterprise Ireland4 shared
Wellington Management4 shared
SR One4 shared
Logos Capital4 shared
Last updated: 8 September 2026